The Company’s Annual Shareholders’ Meeting was held on January 31, 2023, which approved the Company’s financial statements for the period from August 1, 2021 to July 31, 2022, the report on the Company’s activities for the same period, as well as approved operations of all members of the Company’s Supervisory Board and Management Board, and adopted a resolution on loss coverage. The Company’s financial documents were submitted to the Repository of Financial Documents.
4Cell Therapies -